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Diﬀerentiating sepsis from non-infectious systemic
inﬂammation based on microvesicle-bacteria
aggregation†
I. K. Herrmann,*a S. Bertazzo,a D. J. P. O’Callaghan,b A. A. Schlegel,c C. Kallepitis,a
D. B. Antcliﬀe,b A. C. Gordonb and M. M. Stevens*a
Sepsis is a severe medical condition and a leading cause of hospital mortality. Prompt diagnosis and early
treatment has a signiﬁcant, positive impact on patient outcome. However, sepsis is not always easy to diag-
nose, especially in critically ill patients. Here, we present a conceptionally new approach for the rapid diag-
nostic diﬀerentiation of sepsis from non-septic intensive care unit patients. Using advanced microscopy and
spectroscopy techniques, we measure infection-speciﬁc changes in the activity of nano-sized cell-derived
microvesicles to bind bacteria. We report on the use of a point-of-care-compatible microﬂuidic chip to
measure microvesicle-bacteria aggregation and demonstrate rapid (≤1.5 hour) and reliable diagnostic diﬀer-
entiation of bacterial infection from non-infectious inﬂammation in a double-blind pilot study. Our study
demonstrates the potential of microvesicle activities for sepsis diagnosis and introduces microvesicle-
bacteria aggregation as a potentially useful parameter for making early clinical management decisions.
Introduction
Sepsis is the presence of the systemic inflammatory response
syndrome (SIRS) due to infection and represents a potentially
life-threatening condition. It remains a major cause of morbid-
ity and is currently the tenth most common cause of death
overall.1–3 The management of sepsis is technically demanding
and costly, translating to an associated annual multibillion
dollar burden for the healthcare industry.4
There is compelling evidence that early diagnosis of sepsis
is key to improved patient outcomes.5,6 The majority of inten-
sive care unit (ICU) patients exhibit signs of systemic inflam-
mation and up to 93% meet the SIRS criteria at some point
during their ICU stay, yet discriminating a sepsis patient
needing antibiotic treatment from one with non-infectious
SIRS remains challenging.2 Blood cultures require long incu-
bation times (>24 hours) and have a high incidence of false
negatives.7 As a result, making early clinical management
decisions according to blood culture assays is not always poss-
ible. To help guide treatment, research eﬀorts have focused on
surrogate markers of inflammation; large numbers have been
investigated, but few have entered routine clinical application.8
Those that are used (e.g., C-reactive protein (CRP), procalcito-
nin (PCT)) are not always able to consistently discriminate
patients with sepsis from those with non-infectious SIRS.8–10
Diagnostic uncertainty makes it diﬃcult for clinicians to deter-
mine when to provide or withhold antibiotic treatment.5
Failing to provide appropriate antibiotics results in increased
morbidity and mortality, whereas excessive use results in
increased bacterial resistance. Antibiotic resistant bacteria is a
major global healthcare challenge, along with side-eﬀects such
as Clostridium diﬃcile diarrhoea.11
Recently, leukocytes have been shown to release trigger-
dependent microvesicle subpopulations in response to bac-
terial exposure. Microvesicles are nano-sized membrane-bound
fragments released from cells under both physiological and
pathological conditions, with their composition varying
according to both the cell type and the eliciting stimulus.12–19
Timár et al.15 recently investigated the release of microvesicles
from neutrophils in vitro under physiological conditions and
in response to various triggering substances and found that
microvesicles derived from neutrophils exposed to Staphylo-
coccus aureus (S. aureus), showed distinct aggregation with
exogenously added bacteria while significantly less aggregation
was observed with microvesicles from neutrophils not exposed
to bacteria. While there is increasing evidence that microvesi-
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cles undergo specific phenotypic changes in response to trig-
gers,15,16 little is known about their diagnostic potential.
In this study, we investigated the diagnostic potential of
functional microvesicle activity in sepsis using plasma samples
from ICU patients suﬀering from non-infectious SIRS or sepsis.
Moreover, we present a microfluidic chip that allows semi-quan-
titative readouts of microvesicle activity and opens up the possi-
bility of implementing microvesicle activity assays into a
clinically applicable platform for the rapid diagnostic diﬀeren-
tiation of (bacterial) sepsis from non-infectious inflammation.
Results
Microvesicle release from polymorphonuclear cells (PMNs) in
response to bacteria in vitro
To characterize the formation of polymorphonuclear cell
(PMN)-derived microvesicles in response to diﬀerent bacterial
triggers, we studied the process of microvesicle shedding from
PMNs in response to two of the most common etiologic agents
in sepsis, S. aureus (Gram-positive) and Escherichia coli (E. coli)
(Gram-negative), and lipopolysaccharide (LPS) in vitro. Charac-
terization of supernatants by scanning electron microscopy
(SEM) confirmed the presence of microvesicles and Nano-
particle Tracking Analysis (NTA) showed increased concen-
tration of microvesicles in PMN samples exposed to serum-
opsonised S. aureus, E. coli and heat-inactivated S. aureus bac-
teria (bioparticles), with comparable microvesicle size distri-
butions between 50 and 800 nm (Fig. 1a and b). Microvesicles
were stained for neutrophil markers (double staining for
CD11β/CD18 and CD11β/CD177). CD11β/CD18 and CD11β/
CD177-double positive microvesicles were found to be elevated
by a factor of ∼4 compared to control samples in PMNs
exposed to S. aureus (p < 0.01), and elevated by a factor of ∼2.5
and ∼4 in PMNs exposed to E. coli (p < 0.01), respectively
(Fig. 1c). While LPS did not significantly aﬀect the concen-
Fig. 1 Trigger-dependent microvesicle shedding. Scanning electron micrograph (a) and size-distribution assessed by NTA (b) of PMN-derived
microvesicles originating from PMNs incubated with plasma-opsonized S. aureus bacteria, E. coli, LPS, heat-inactivated bacteria bioparticles or
vehicle (HBSS). PMN-derived CD11β/CD18 and CD11β/CD177-double positive events assessed by ﬂow cytometry as a function of bacterial triggering
agent (n = 3) (c). Scanning (d,e) and transmission electron micrographs (f,g) of PMNs showing pronounced membrane budding and shedding of
microvesicles following incubation with opsonised S. aureus particles for 30 minutes (arrow indicates S. aureus particle) (e,g) compared to PMNs
incubated with HBSS (d,f ). 3D-Tomographies and outer surface reconstructions of PMN incubated with S. aureus further conﬁrmed the constriction
of vesicles from the outer membrane seen in TEM (h). Raman spectroscopy maps of PMN incubated with (top, I) or without (bottom, II, control) bac-
teria showed lipid droplets and peri-membranous accumulation of glycogen granules in stimulated PMNs (I) compared to control (II) (i).
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tration of CD11β-positive microvesicles, heat-inactivated
S. aureus, E. coli and bioparticles showed comparable eﬀects to
live bacteria. Together, these in vitro results suggested that
microvesicle release was triggered by the presence of opsonised
(bacteria) particles.
We next characterized the process of microvesicle shedding
from PMNs in vitro using advanced electron microscopy and
spectroscopy techniques. Microvesicle release was evaluated in
samples prepared by incubating isolated human PMNs with or
without serum-opsonized S. aureus for 30 minutes. Scanning
electron micrographs showed pronounced membrane budding
in PMNs exposed to S. aureus compared to resting PMNs
(Fig. 1d and e). Transmission electron micrographs of thin sec-
tions of PMNs containing phagocytised S. aureus bacteria
confirmed increased membrane budding and formation of
microvesicles (Fig. 1f and g). Formation of glycogen granule
clusters, translocation and peri-membranous massing of glyco-
gen granule aggregates, and shipping of cytoplasmatic micro-
vesicles containing glycogen granules were observed in PMNs
exposed to bacteria, while glycogen granules remained well-
dispersed in the cytoplasm of unstimulated PMNs (Fig. 1f and
g). 3D-Tomography of PMNs further confirmed constriction of
vesicular structures from the cellular membrane (Fig. 1h). Con-
focal Raman spectroscopy maps showed glycogen granule
aggregation (Raman shift of glycogen20: 485 cm−1) in response
to S. aureus exposure (Fig. 1i). While very few glycogen clusters
were detectable in control samples, which indicated that the
20 nm granules remained well dispersed, glycogen clusters
were detected in samples exposed to S. aureus, mostly in peri-
membranous regions. These findings indicated that exposure
of PMNs to bacteria led to peri-membraneous accumulation of
glycogen (as previously reported by Robinson et al.21) and the
shedding of microvesicles enriched in glycogen.
Characterization of microvesicles in plasma samples from
sepsis and SIRS patients
In order to assess the in vivo relevance and diagnostic potential
of PMN-derived microvesicles in diﬀerentiating bacterial
sepsis from non-infectious SIRS, we analysed heparinised
plasma samples from 22 brain-injured ICU patients (patient
characteristics, see ESI Table S1†). The plasma samples had
been collected within 72 hours of ICU admission. Twelve
patients had non-infectious SIRS (SIRS criteria ≥2) as part of
their underlying condition. Two patients presented with SIRS
criteria <2 and eight patients were diagnosed with sepsis
(6 patients) or suspected sepsis (2 patients) based on their
clinical presentation (SIRS criteria ≥2) and blood culture
results. Among the sepsis patients with positive blood culture,
three patients had a Gram-positive blood culture and three
patients had a Gram-negative blood culture. For statistical ana-
lysis, patients with SIRS criteria <2 and non-infectious SIRS
patients were classified as control group (n = 14) while patients
with known or suspected sepsis were classified as sepsis group
(n = 8). Analysis of clinical data based on the SIRS criteria
showed no significant diﬀerences between the control and
sepsis groups (see ESI Table S1†). Commonly used concen-
trations of sepsis biomarkers such as C-reactive protein (CRP,
p = 0.081, β = 0.7) and procalcitonin (PCT, p = 0.056, β = 0.84)
showed no diﬀerences between the two groups, although stat-
istical power was limited (ESI Fig. S1a and b†).
Microvesicle populations were isolated from plasma by
ultracentrifugation (100 000g for 1 hour at 4 °C) and character-
ized by NTA and flow cytometry. No diﬀerence in microvesicle
size or concentration was found between the sepsis and
control groups by NTA (ESI Fig. S1c and d†). Both CD11β/CD18
and CD11β/CD177-double positive microvesicle concentrations
were elevated in the sepsis group compared to the control
group (CD11β/CD18-double positive microvesicles, p = 0.01, β =
0.40; CD11β/CD177-double positive microvesicles, p = 0.008,
β = 0.28) (ESI Fig. S1e†).
Functional activity of plasma-derived microvesicles in SIRS
and sepsis patients
We characterized microvesicle plasma populations in clinical
samples according to three characteristic processes altered
during sepsis: inflammation, procoagulant activity, and bac-
teria aggregation activity. The proinflammatory, procoagulant
and aggregation activity of isolated microvesicles were
measured and evaluated regarding their sensitivity and speci-
ficity for sepsis diagnosis (Fig. 2a). First, the inflammatory
phenotype of the microvesicle isolates was determined in an
endothelial cell-based assay for both sepsis and control
patients. Human endothelial cells were exposed to patient
plasma-derived microvesicles for 24 hours and the release of
Lactate Dehydrogenase (LDH, indicative for cell death) and
Interleukin-6 (IL-6) was quantified. No microvesicle-induced
cell death was observed (Fig. 2a and b). While exposure of
endothelial cells to plasma-derived microvesicles led to slightly
elevated IL-6 protein levels (2-fold increase relative to cells not
exposed to microvesicles, p = 0.03), we detected no significant
diﬀerence between the inflammatory activity of microvesicles
from sepsis and control group patients (Fig. 2c). The inflam-
matory activity of both microvesicle populations was low com-
pared to the IL-6 expression in LPS-stimulated endothelial
cells (7-fold increase of IL-6 protein expression, p < 0.01). Cyto-
kine levels (Interleukin-1α, IL-6, and Tumour Necrosis Factor-
α) in microvesicle isolates were below assay detection limits
(<10 pg mL−1).
Microvesicle procoagulant activity in patient plasma
samples was measured based on phospholipid-mediated
thrombin activation (Fig. 2a and d). Additionally, plasma clot-
ting time was measured by adding microvesicles isolated from
patient samples to re-calcified microvesicle-depleted citrated
plasma and then measuring turbidity change due to fibrino-
gen-fibrin polymerization (Fig. 2a and e). We observed that the
procoagulant activity of the microvesicle population in the
sepsis group was elevated (p = 0.04, β = 0.45). In keeping with
the higher procoagulant activity of microvesicles, plasma clot-
ting time was shortened in those samples exposed to micro-
vesicles from septic patients (p = 0.04, β = 0.16).
Finally, we measured bacteria aggregation activity of
plasma-derived microvesicles. Patient plasma-derived micro-
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vesicles were incubated with a stained S. aureus bacteria stan-
dard and bacteria-microvesicle aggregation was measured by
counting aggregates larger than 5 µm using confocal
microscopy (Fig. 2a and f). The number of large bacteria aggre-
gates was significantly higher in sepsis patient samples com-
pared to controls (p < 0.01, β = 0.07) (Fig. 2g).
Receiver Operating Characteristics (ROC) with corres-
ponding area under the curve values (AUC) were calculated for
clinically used sepsis biomarkers (CRP and PCT) and micro-
vesicle characteristics (Fig. 2h); the closer AUC is to 1, the
better the diagnostic performance. ROC analyses of the control
versus the sepsis group showed significantly diﬀerent AUC
values for both coagulation assays (procoagulant activity assay:
AUC = 0.78 ± 0.10, p = 0.04; plasma clotting time assay: AUC =
0.74 ± 0.11, p = 0.04). ROC analysis of the bacteria aggregation
assay resulted in an AUC value of 0.92 ± 0.08 (p < 0.01). Posi-
Fig. 2 Microvesicle-based functional activity in clinical samples. Microvesicle-induced cell-death and inﬂammatory response in an endothelial cell
model (a). Lactate dehydrogenase (LDH) release (indicative for cell death) (b) and interleukin-6 expression (c) of endothelial cells in response to
microvesicle exposure for 24 hours. Microvesicle procoagulant activity was measured by assessing phosphatidylserine-induced thrombin activation
(a,d) and microvesicle-induced changes in plasma clotting time in re-calciﬁed plasma (a,e). Microvesicle-triggered bacteria aggregation (a). Bacteria
aggregate size was quantiﬁed for control group and sepsis patient microvesicle isolates after incubation with stained (green) S. aureus bacteria based
on confocal ﬂuorescence image analysis (f,g). Corresponding receiver operating characteristic area under the curve values for commonly used bio-
markers (C-reactive protein (CRP), Procalcitonin (PCT)) and microvesicle activites (h).
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tive correlations were found between CD11β-CD18-double posi-
tive microvesicles and bacteria-aggregation (Spearman’s rho:
0.41, p = 0.049) as well as CD11β-CD177-double positive micro-
vesicles and aggregation (Spearman’s rho: 0.45, p = 0.033).
Microvesicle activity in blood plasma from an experimental
sepsis animal model
In order to better understand the relevance of microvesicles
during sepsis progression and evaluate whether microvesicle
aggregation could serve as an early sepsis marker, we evaluated
microvesicle concentration and aggregation activity of plasma-
derived microvesicles in a standard rat model of polymicrobial
septic peritonitis (Fig. 3a). We analysed plasma samples col-
lected before caecal ligation and puncture (CLP)22,23 surgery
and every 24 hours for up to 96 hours. The overall survival in
the CLP group was 75% (ESI Fig. S2a†) and a distinct weight
loss up to 7% was observed in the CLP group in the first
24 hours (p < 0.01) (ESI Fig. S2b†). The concentration and size
of microvesicles isolated from plasma were in the same order
as for the patient plasma samples and no significant diﬀer-
ence between the SHAM and the CLP group was found in
terms of size or concentration at any of the time points. The
plasma concentration of CD11β/CD18-double positive micro-
vesicles was increased in the CLP-group, which reached peak
concentrations at 48 hours and then gradually decreasing to
values comparable to baseline 96 hours after sepsis induction
(Fig. 3b). Aggregation activity in samples was significantly
diﬀerent between the SHAM and the CLP group with an AUC
(t24) = 0.76 ± 0.11, (p = 0.041) at 24 hours and an AUC (t48) =
0.89 ± 0.09, (p < 0.01) at the 48 hour time point (Fig. 3c and d).
Again, aggregation activity significantly correlated with
CD11β/CD18-double positive microvesicles (Spearman’s rho:
0.72, p < 0.01).
Characterization of microvesicle-bacteria aggregates
In order to better understand the nature of the microvesicle-
bacteria aggregates, we used an in vitro analysis to further
characterize their properties. The CD11β-positivity of the
aggregating human PMN-derived vesicles was confirmed by
immunostaining (Fig. 4a) and transmission electron micro-
graphs of microvesicle-bacteria aggregates were recorded
(Fig. 4b). The microvesicle-concentration dependence of bac-
teria aggregation was confirmed by serially diluting microvesi-
cle isolates from PMNs exposed to S. aureus (in vitro). If
microvesicle isolates were diluted with HBSS (1 : 10), no signifi-
cant aggregation was detected, while microvesicle isolates
incubated with bacteria at their original concentration (or if
they became concentrated by ultracentrifugation) showed more
pronounced aggregation (Fig. 4c).
Microfluidic chip to measure aggregation activity
Based on the results of the aggregation activity, we developed a
microfluidic chip that allowed semi-quantitative assay read-
outs of aggregation activity. We used heat-inactivated serum-
opsonized S. aureus bioparticles as the aggregation agent. Fol-
lowing the incubation of bioparticles with diﬀerent concen-
trations of PMN-derived microvesicles, the sample was filtered
through a weir-filter chip. The performance of a microfluidic
weir-filter chip with slits of 5, 10 and 20 µm was evaluated for
the separation of aggregated bacteria. Fluorescence intensity
was measured at the inlet and outlet of the chip and was
indicative of the degree of sample aggregation (Fig. 4d). While
the 5 µm slit chip demonstrated significant clogging, the 10
µm slit filter allowed separation of bioparticle aggregates from
single bioparticles. The degree of aggregation, as determined
by the ratio of the fluorescence intensity at the inlet and
outlet, correlated well with the image analysis and the micro-
vesicle concentration (Spearman’s rho 0.87, p < 0.05) (Fig. 4e).
For validation purposes, a blinded trial was performed
including 6 samples from a temporally diﬀerent set of
patients. A total of 12 samples (from 6 sepsis patients and 6
non-infectious SIRS patients) were analysed in the blinded
trial using a weir-filter chip with a slit height of 10 µm. We
found that 10 out of 12 samples were assigned to the correct
group (based on clinical diagnosis). With a cut-oﬀ value of 0.9
for the chip fluorescence readout (outlet/inlet), one sample
was false positive and one sample was borderline (with a value
of 0.89) (Fig. 4f). The correlation between the chip readout and
the CD11β-CD177-double positive microvesicle concentration
was −0.67 (p < 0.05).
Fig. 3 Microvesicles in plasma samples from an experimental sepsis
model. Caecal ligation and puncture (CLP) procedure in rats (a). Time-
dependent concentration of neutrophil-derived CD11β/CD18-double
positive microvesicles assessed by ﬂow cytometry (b). Aggregation of
S. aureus bacteria standard with microvesicle isolates from animal plasma
at the 24 and 48 hour time point (c) and corresponding ROC curves (d).
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Discussion
This is the first study investigating the diagnostic potential of
PMN-derived microvesicles for the diﬀerentiation of infectious
(sepsis) and non-infectious systemic inflammation. We found
that exposure of PMNs to Gram-negative and Gram-positive
bacteria induced significant shedding of distinct microvesicle
populations with increased bacteria aggregation activity and
high specificity towards infection in experimental as well as
clinical settings. This study corroborates and validates increas-
ing evidence that microvesicles undergo stimulus-dependent
phenotypic changes, and paves the way for microvesicle-based
diagnostics.19,24
While diﬀerences in clinical parameters and biomarker
concentrations between sepsis patients and healthy volunteers
are often pronounced, discriminating patients with sepsis
from those with non-infectious SIRS remains challenging. We
found the proinflammatory activity of microvesicles was com-
parable across the patient groups, but the procoagulant and
aggregation activities of microvesicles were significantly
increased in sepsis. In particular, aggregation activity showed
a high specificity and sensitivity to infection over inflam-
mation in our small, heterogeneous patient cohort (which
included Gram-negative, Gram-positive, and possibly poly-
microbial infections).
Together with the findings from Timár et al.15 and
Oehmcke et al.,16 our results strongly suggest that there is an
infection-specific shift in microvesicle properties that lead to
increased aggregation activity. Since this increased aggregation
activity is initiated by the innate immune system in response
to infection rather than inflammation, this activitiy may facili-
tate the early diﬀerentiation of non-infectious and infectious
inflammatory processes. The results obtained in the murine
sepsis model suggested an increase of circulating leukocyte-
derived microvesicles already in the early phase of sepsis,
which reached values comparable to baseline once abscess
formation in CLP animals was under control, and which
coincided with the stabilization of body weight. The PMN-
derived microvesicle isolates from animal plasma samples
showed similar aggregation activity and specificity/sensitivity
for infection as previously observed for clinical samples, which
suggested that these phenomena are a collectively preserved
response to early sepsis. Our microfluidic chip opens up the
possibility of evaluating microvesicle activity in a clinical
setting for the rapid diagnostic diﬀerentiation of (bacterial)
sepsis from non-infectious inflammation.
Conclusions
In conclusion, our study demonstrates the use of microvesicle-
based functional activities for the rapid (≤1.5 hour) diagnosis
of sepsis. Our assay serves as a potentially attractive comp-
lementary test to currently-used inflammation-based surrogate
Fig. 4 Microvesicle-bacteria aggregation – characterization and microﬂuidic chip assay. Confocal images of stained S. aureus bacteria before and
after incubation with PMN-derived microvesicles showed co-localization of CD11β-stained microvesicles (red) with aggregated bacteria (green) (a).
Transmission electron micrograph of aggregated bacteria (b). Increasing the microvesicle concentration lead to more pronounced bacteria aggrega-
tion (low (1), intermediate (2) and high (3) microvesicle concentration) (c). Geometry of the weir-type ﬁlter microﬂuidic chip with four separation
channels (d). Correlation of the change in ﬂuorescence intensity (outlet/inlet, x) of the chip and results from image analysis (y) and microvesicle con-
centration measurements (z) (e). Results from the blinded test showing chip readouts for the control (n = 6) and sepsis (n = 6) patients, and readouts
of the negative control (NC) and positive control (PC) using a weir-ﬁlter chip with a 10 µm slit (f ).
Paper Nanoscale
13516 | Nanoscale, 2015, 7, 13511–13520 This journal is © The Royal Society of Chemistry 2015
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
5/
02
/2
01
6 
14
:3
2:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
markers or blood cultures in making early clinical manage-
ment decisions regarding the administration of antibiotics.
This is particularly important as antibiotic resistance rates
have increased over the last decade and resistant microbes
have been identified as a major global healthcare chal-
lenge.25,26 Additionally, our findings further support the sup-
position that the development of diagnostic assays for sepsis
may require exploring new avenues, including probing of the
cellular response and degree of cell activation, e.g., by analysing
nano-sized cell-derived vesicles. The developed microfluidic
weir-filter chip provides a platform that opens microvesicle
aggregation to evaluation in a large patient cohort in real time;
in a larger cohort, potentially confounding factors such as
patient heterogeneity, neutropenia, surgery and trauma injury,
and masking due to (antibiotic) therapy can also be examined.
While our study is based on a small patient number, the good
diagnostic performance in both an experimental sepsis model
and an unselected, heterogeneous ICU patient set suggests
future potential for microvesicles as infection-specific markers.
Experimental
Study approval
Ethical approval was given (North London REC 3 reference:
10/H0709/77). Written informed consent was received from par-
ticipants prior to inclusion in the study. Previously collected
samples from 28 patients were analysed. Patient characteristics
and inclusion/exclusion criteria can be found in the ESI Tables
S1 and S2.† Animal studies were conducted in accordance with
the Institutional Animal Care and Use Committee (approved by
the veterinary oﬃce of Zurich, Switzerland, 14/2011).
Polymorphonuclear cell isolation
PMNs were isolated from healthy volunteers following pre-
viously described procedures.27 Briefly, 20 mL of blood was
drawn using acid citrate dextrose (ACD, Sigma Aldrich) as anti-
coagulant. Red blood cells were lysed using red blood cell lysis
buﬀer (10 mM KHCO3, 155 mM NH4Cl (both from Sigma
Aldrich) in Milli-Q water (18 MΩ, sterile filtered) and white
blood cells were pelleted by centrifugation at 350g for
10 minutes. White blood cells were then layered on a Ficoll
gradient (Histopaque 1077, Sigma Aldrich) and centrifuged for
30 minutes at 350g. Flow cytometry confirmed >95% of the iso-
lated cells were CD11β-positive. PMN in vitro experiments were
repeated at least three times with three diﬀerent batches of
PMNs (n ≥ 3).
Bacteria and lipopolysaccharide
Staphylococcus aureus subsp. aureus Rosenbach (S. aureus, ATCC
29213) bacteria were cultured in suspension in Tryptic Soy
broth (Sigma Aldrich) and Escherichia coli (Migula) Castellani
and Chalmers (E. coli ML35, ATCC 43827)) were cultured in LB
broth (Sigma Aldrich) in an incubator at 37 °C on a shaker
(250 rpm). Heat-inactivated bacteria were prepared by incubat-
ing the bacteria suspension at 90 °C for 1 hour. For experi-
ments, bacteria and bacteria bioparticles (LifeTechnologies)
were washed in HBSS and opsonised with human serum (from
human male AB plasma, sterile filtered, Sigma Aldrich) for
30 minutes at 37 °C following the protocol by Timár et al.15
After opsonisation, bacteria were washed with HBSS. The stock
concentration was set to OD600 ∼ 1 for bacteria and to 109 per
mL for bioparticles. Lipopolysaccharide (from E. coli 055:B5,
Sigma Aldrich) was dissolved in PBS at a stock concentration
of 10 mg mL−1 and further diluted as needed.
Microvesicle characterization – in vitro samples
Freshly isolated human PMNs were then incubated with opso-
nised bacteria for 30 minutes and supernatants were collected
for further analysis (100 000g for 1 hour at 4 °C, Beckman
Ultracentrifuge). Microvesicles were characterized by NTA
(LM10, Nanosight) and Flow Cytometry (Fortessa, BD Bio-
sciences). For NTA measurements, microvesicles were
measured directly or diluted 1 : 10 in triple-filtered HBSS
where necessary. The same camera settings (camera level 13)
were used for all measurements and each sample was
measured at least three times. For flow cytometry, microvesi-
cles were either analyzed unstained or double-stained with
leukocyte antibodies (CD11β, CD177 or CD18). For staining,
FITC-conjugated anti-human-CD177 (MEM-166, Mouse IgG1,
Abcam) or FITC-conjugated anti-human-CD18 (TS1/18, Mouse
IgG1, κ, BioLegend) and Alexa-647-conjugated anti-human-
CD11β antibodies (M1/70, Rat IgG2b, κ, BioLegend) were used at
concentrations of 1 µg mL−1 (1 hour, 37 °C in the dark) and
double positive events were counted in the microvesicle gate
(events ≤1 µm beads) using counting beads (CountBright,
LifeTechnologies). Isotype controls and diﬀerential TritonX lysis
(0.1% v/v) were used to exclude non-specific binding and binding
to non-vesicular substructures (protein aggregates, etc.).28
Electron micrographs
S. aureus bacteria were opsonised with human serum (human
serum, Sigma Aldrich). Freshly isolated PMN were incubated
with serum-opsonized S. aureus bacteria for 30 minutes at
37 °C. Following incubation, supernatants were collected for
further analysis, and cells were re-suspended and fixed with
4% v/v paraformaldehyde (PFA, 16% v/v Paraformaldehyde
aqueous solution, Electron Microscopy Sciences, Hatfield, PA,
diluted in PBS) and 0.2% v/v glutaraldehyde (Grade II, 25% v/v
in H2O, Sigma Aldrich, diluted in PBS) for 12 hours and centri-
fuged at 3000g for 10 minutes. For SEM, samples were de-
hydrated with ethanol (30% v/v, 50%, 70%, 90%, 100% (3×),
5 minutes each), re-suspended in hexamethyldisilazane
(HMDS, Sigma Aldrich) and dried on a glass cover slip.
Samples were secured to an aluminium sample holder with
carbon tape, and silver paint was applied to the area immedi-
ately surrounding each sample, which was then coated with
5 nm carbon (Quorum Technologies Turbo-Pumped Thermal
Evaporators model K975X) and 5 nm chromium in a sputter
coater (Quorum Technologies Sputter Coater model K575X).
Following the coating procedure, samples were imaged by SEM
(Gemini 1525 FEGSEM), operated at 5 kV.
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For TEM and 3D tomography, samples were fixed in a 4%
(v/v) formaldehyde (Sigma, BioReagent, ≥36.0%) with 0.2%
(v/v) glutaraldehyde (EMS [Electron Microscopy Sciences]) solu-
tion in PBS at room temperature for 15 minutes. Samples were
washed three times with cacodilate buﬀer (EMS) and osmi-
cated with osmium tetroxide in 2% (w/v) cacodilate buﬀer for
30 minutes. After that, samples were washed five times with
deionized water and then dehydrated through a graded
ethanol (Sigma, ACS reagent 99.5%) series two times for each
concentration (20, 30, 40, 50 70, 80, 90, 100, 100, 100% (v/v))
for 5 minutes in each solution. After dehydration, samples
were infiltrated with Epon Resin (EMS) diluted in ethanol at
3 : 1, 2 : 1, and 1 : 1 for 1 hour each, and then overnight at 1 : 2.
The solution was then replaced with pure resin, which was
changed twice in the first 12 hours and then allowed to infil-
trate again overnight. Samples were placed in an oven at 60 °C
and left to cure overnight. Cured resin blocks were sectioned
at 100 nm in an ultramicrotome (Leica) and immediately
placed on carbon-coated copper grids. The grids were imaged
in the TEM at 80 kV (JEOL 2000FX TEM).
Resin blocks were also secured to a SEM aluminium sample
holder with carbon tape and silver paint applied to the area
immediately surrounding the sample (to maximise conduc-
tivity), and then coated with 5 nm of chromium in a sputter
coater (QuorumTechnologies model K575X). Following the
coating procedure, samples were introduced into an SEM/
Focused Ion Bean (Carl Zeiss – Auriga) with gallium ion bean
operated at 30 kV. A region over the cells was milled using
4 nA current. After that, the region exposed by the first milling
was polished with 240 pA current and imaged by a backscatter-
ing detector with the electron bean operating at 1.5 V. To gene-
rate a 3D-surface model, individual high resolution in situ
cross-section electron micrographs of micropattered cells were
stacked using Amira software.
Raman spectroscopy (maps and spectra)
Magnesium fluoride (MgF2) slides were pre-treated with BD
Cell-Tak™ Cell and Tissue Adhesive in a 48-well tissue culture
plate (BD Biosciences, 5.2 µL in 300 µL of sodium bicarbonate
buﬀer, pH = 8 for 40 minutes at room temperature). Following
two washing steps with ddH2O, MgF2 slides were incubated
with the cell suspension in PBS for 30 minutes. Slides were
then fixed with 4% v/v PFA and washed gently with PBS before
analysis. Raman spectral imaging was performed on a confocal
Raman microscope (alpha300R+, WITec, Ulm, Germany).
A 532 nm laser (Compass Sapphire, Coherent, Gottingen,
Germany) was used for excitation. The laser beam was focused
through a 63×/1.0 NA water immersion microscope objective
lens (W Plan-Apochromat, Zeiss, Oberkochen, Germany). The
Raman spectroscopy signals were dispersed by a grating (600 g
mm−1) spectrograph (UHTS 300, WITec, Ulm, Germany) and
the spectra acquired with a thermoelectrically cooled CCD
detector (Newton DU970N-BV-353, Andor, Belfast, UK) with a
spectral resolution of 3 cm−1. Raman spectroscopy images
∼150 × 150 μm were produced with 400 nm spatial resolution,
1 s integration time and one accumulation per pixel. Spectral
collection was centered at 2000 cm−1 (0–3000 cm−1). The
Control FOUR software (version 4.0, WITec) was used for
measurement and Project FOUR Plus (version 4.0, WITec) for
spectral data processing.
Clinical plasma sample analysis
Previously collected plasma samples from 22 intensive care
unit patients suﬀering from either from non-infectious (n =
14), infectious SIRS (n = 8) were analysed (Patient character-
istics and inclusion/exclusion criteria can be found in the ESI
Tables S1 and S2†). All assays were carried out in duplicate
(two technical repeats). Blood samples had been collected
from an indwelling line into a Heparin Vacutainer tube (5 mL)
and stored on ice (maximum 5 minutes) until the first cen-
trifugation step carried out at 2000g for 10 minutes.
Plasma biomarker measurement
Procalcitonin (PCT) levels were measured in all samples by
enzyme-linked immunoassay (ELISA, Abcam) following the
manufacturer’s instructions.
Characterization of plasma samples
Plasma samples were pre-processed by centrifugation at 3000g
for 30 minutes and filtration through a 5 µm filter (Millex
Filter Unit, Millipore) in order to remove cell debris. Where
indicated, microvesicles were isolated from plasma samples by
ultracentrifugation (diluted 1 : 100 in filtered HBSS, 100 000g
for 1 hour at 4 °C, Beckman Ultracentrifuge). The isolated
microvesicles were re-suspended in the same volume of filtered
HBSS as the original plasma volume. Plasma samples and
samples containing isolated microvesicles were stored at
−80 °C, and repeated freeze–thaw cycles were avoided. The
plasma protein content of ultracentrifuged samples was below
1% (v/v). Blood count, temperature, heart rate, and C-reactive
Protein levels (CRP) were available for all patients included in
this study.
Microvesicle characterization – plasma samples
For NTA, plasma samples were analysed directly or following
ultracentrifugation using the same camera level (CL 13) for all
samples. For flow cytometry, filtered plasma samples were
diluted 1 : 10 in triple-filtered phosphate buﬀered saline
(100 nm filter unit, Millipore) and stained following the pro-
cedure described above. Double-stained and unstained plasma
samples were analysed using the same gating and post-proces-
sing (Triton X lysis) procedures as described above for the ana-
lysis of in vitro samples. Double positive events were counted
in the microvesicle gate (events ≤1 µm beads) using counting
beads (CountBright, LifeTechnologies).
Microvesicle-based functional activity assays. inflammatory
response assay
For the inflammatory response assay, human umbilical vein
endothelial cells (HUVEC, Lonza) were seeded in 48-well plates
at 25 000 cells per well in endothelial cell growth medium
(EGM) supplemented with 10% v/v fetal bovine serum (FBS).
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For the experiment, FBS-free, phenol red-free endothelial cell
basal medium (EBM) was used. Part of the wells were stimu-
lated with 0.1 and 1 µg mL−1 LPS (positive controls). Isolated
microvesicles were then added to the wells and incubated for
24 hours at 37 °C. LDH release in the supernatants was
measured using the Non-Radioactive Cytotoxicity Assay Kit
(Promega UK, Southampton , UK). Inflammatory response was
quantified using a multiplex cytokine assay kit (4-plex kit,
Quansys Biosciences, Logan, UT).
Procoagulant activity assay
The procoagulant activity of microvesicles was measured using
a commercially available ZYMUPHEN MP Activity Kit (Aniara,
West Chester, OH) and a plasma clotting time assay. For the
ZYMUPHEN MP Activity Assay, plasma samples were diluted
1 : 20 and incubated in an AnnexinV coated 96-well plate. Fol-
lowing a washing step, Factor Xa-Va, calcium and prothrombin
were added. The phospholipid-induced prothrombin-thrombin
activation was measured using a thrombin substrate and
absorbance was measured at 405 nm using a plate reader. For
the plasma clotting time assay, citrated platelet free plasma
from a healthy volunteer was centrifuged at 100 000g for 1 hour
at 4 °C in order to sediment microvesicles. The microvesicle-free
plasma was then added to a 96-well plate (100 µL per well). Five
microliter of isolated microvesicles from patient samples were
added to each well and incubated for 15 minutes at 37 °C. Fol-
lowing incubation, the citrate plasma was re-calcified by adding
65 µL per well of 50 mM calcium chloride solution and fibrino-
gen-fibrin polymerization was observed at 405 nm using a plate
reader (kinetic measurement, for 100 minutes, 1 measurement
per 30 seconds, at 37 °C). Plasma with HBSS was used as nega-
tive control, plasma plus amorphous silica nanoparticles (1 mg
mL−1) served as positive control.
Bacteria aggregation assay
S. aureus bacteria were stained using a SYTO 9 green fluo-
rescent nucleic acid dye (Invitrogen) following the manufac-
turer’s protocol and diluted to OD600 ∼ 1. For the bacteria
aggregation assay, isolated microvesicles were then mixed with
the stained bacteria standard in a 10 : 1 volume ratio and incu-
bated at 37 °C for 30 minutes in a glass chamber slide (IBIDI,
8 well chamber slide). Bacteria aggregation was imaged using
a confocal microscope (Leica SP5, 20× dry objective). Bacteria
aggregates larger than >5 µm were counted using ICY/Image J.
Animal samples
Stored heparinised plasma samples from 12 Wistar rats
(Charles River Laboratories Inc.) that underwent CLP (midline
laparotomy, 10% ligation of the cecum, single puncture with a
18G needle) and 10 SHAM rats (midline laparotomy, luxation
of cecum, incision of ligament, reposition) were obtained from
diﬀerent time points: 0, 24, 48, 72 and 96 hours after surgery.
The plasma had been prepared by centrifuging the collected
blood at 2500g, for 10 minutes at 4 °C, filtration through a
5 µm filter (Millex Filter Unit, Millipore) and samples had
been stored at −80 °C. Microvesicle analysis was performed as
described above. For flow cytometry, FITC mouse anti-rat
CD18 (WT3, IgG1, AbD Serotec) and Alexa-647 anti-rat CD11β
(OX-42, IgG2a, κ, BioLegend) were used for double staining at
a concentration of 1 µg mL−1.
Microfludic chip
A weir-filter polycarbonate chip with weir-filter slit heights of
5, 10 and 20 µm and pipette adapters were purchased (Micro-
fluidic Chip Shop, Jena, Germany). The samples containing
isolated microvesicle were incubated with serum-opsonised S.
aureus bioparticles for 30 minutes and filtered through the
weir-filter chip. The fluorescence intensity (488 nm excitation,
530 nm emission) was measured at the chip inlet and the
outlet immediately after, resulting in a total time-to-result
(including the microvesicle isolation step) of 1.5 hours.
Statistics
Two groups (control group versus sepsis patients or SHAM versus
CLP) were compared using the Mann-Whitney-U test (two-
sided). ROC curves were calculated for the two groups based on
the clinical classification. AUC values were extracted and ana-
lysed using the ROC tool in MedCalc/Origin. For correlation ana-
lyses, Spearman’s rho coeﬃcients (pair-wise) were calculated in
Origin. p-Values <0.05 were considered statistically significant.
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